A study on miRNA371 for newly diagnosed germ cell tumors
Part of Cancer clinical trials.
This study is looking at a new marker called miRNA371 in people newly diagnosed with germ cell tumors. The goal is to see if it can help predict relapse and guide treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with a germ cell tumor (confirmed by tissue or blood tests).
- You are willing to give blood samples for the study.
- If you are a man with stage I testicular cancer, your orchiectomy (surgery to remove the testicle) must have been done within the last 42 days.
- You have had initial scans and blood tests (like tumor markers) done within the last 42 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug for people with advanced solid tumors, especially ovarian, fallopian tube, peritoneal, endometrial, or germ cell cancers that have a specific marker called CLDN6. The goal is to see if the drug is safe and tolerable.
This trial tests whether a blood test called miRNA-371 can detect active germ cell tumors in patients who have had surgery or are being watched. It may help guide treatment decisions without needing extra biopsies or scans.
This study looks at tiny genetic signals called microRNAs to see if they can help identify or track testicular cancer. It may help doctors recognize testicular cancer more accurately and decide what to do next.
This trial looks for signs of cancer DNA in your blood (circulating tumor DNA) to see if it can help track germ cell tumors. It may help doctors find out if your cancer is coming back earlier.
This trial looks at tiny molecules in the blood to help diagnose ovarian germ cell tumors. It compares results from people with malignant (cancerous) tumors, benign (non-cancerous) tumors, and those without any gynecologic condition.
This study looks at tiny molecules called microRNAs in the blood of people with either small testicular tumors (less than 2 cm) or leftover lymph node masses after chemotherapy for testicular cancer. The goal is to see if these microRNAs can help guide treatment decisions.
Hear when a new Testicular Germ Cell Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.